<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36741231</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases.</ArticleTitle><Pagination><StartPage>9195157</StartPage><MedlinePgn>9195157</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9195157</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/9195157</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Anti-Ro60 and anti-Ro52 antibodies are associated with different connective tissue diseases (CTDs). However, the clinical significance of anti-Ro antibodies is not always consistent among different global regions. The aim of this study was to investigate the clinical characteristics of patients with anti-Ro antibodies.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 1596 inpatients with anti-Ro antibodies were included in the study. Demographic, clinical, and serological data were compared between individuals with different profiles of anti-Ro antibodies: patients with anti-Ro52 antibodies alone, patients with anti-Ro60 antibodies alone, and patients with combined anti-Ro52 and anti-Ro60 antibodies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 1596 patients, 1362 (85.3%) were female, the mean age was 45.5 years, and systemic lupus erythematosus (SLE) (46.0%) and Sjogren's syndrome (SS) (19.0%) were the most common CTD diagnoses. Among the patients with anti-Ro52 antibodies alone, idiopathic inflammatory myopathy (18.8%) and SLE (17.6%) were the most common CTD diagnoses. The coexistent autoantibodies of this group were significantly lower compared with those of the other two groups, while the presence of anti-Jo1 antibodies were significantly higher compared with those of the other two groups (3.7% vs. 0.6% vs. 1.9%, <i>p</i> = 0.029). In addition, the patients with isolated anti-Ro52 antibodies were more likely to suffer from interstitial lung disease (35.5% vs. 11.3% vs. 13.7%, <i>p</i> &lt; 10<sup>-4</sup>) and pulmonary arterial hypertension (10.1% vs. 5.3% vs. 3.6%, <i>p</i> = 0.001) compared with the other two groups of patients. Compared with patients with isolated anti-Ro52 or anti-Ro60 antibodies, the patients with combined anti-Ro52 and anti-Ro60 antibodies were more likely to suffer from xerophthalmia and xerostomia. Furthermore, hypocomplementemia, hyperglobulinemia, and proteinuria were particularly prevalent in patients with anti-Ro60 antibodies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Different profiles of anti-Ro antibodies were significantly associated with clinical phenotypic features in CTDs, indicating the potential diagnostic and prognostic value of these antibodies in clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Hai-Tao Yang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hai-Tao</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Xiao-Ping</ForeName><Initials>XP</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jie-Wen</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Xiao-Ling</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cui-Lian</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li-Xiong</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu-Lan</ForeName><Initials>YL</Initials><Identifier Source="ORCID">0000-0001-5923-1899</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong-Zhou</ForeName><Initials>DZ</Initials><Identifier Source="ORCID">0000-0003-3766-6562</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092522" MajorTopicYN="N">Clinical Relevance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>3</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36741231</ArticleId><ArticleId IdType="pmc">PMC9891828</ArticleId><ArticleId IdType="doi">10.1155/2023/9195157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scofield R. H. Autoantibodies as predictors of disease. Lancet . 2004;363(9420):1544&#x2013;1546. doi: 10.1016/S0140-6736(04)16154-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16154-0</ArticleId><ArticleId IdType="pubmed">15135604</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan E. K., Hamel J. C., Buyon J. P., Tan E. M. Molecular definition and sequence motifs of the 52-kd component of human ss-a/ro autoantigen. The Journal of Clinical Investigation . 1991;87(1):68&#x2013;76. doi: 10.1172/JCI115003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI115003</ArticleId><ArticleId IdType="pmc">PMC294993</ArticleId><ArticleId IdType="pubmed">1985112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolin S. L., Steitz J. A. The ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the ro rnas. Proceedings of the National Academy of Sciences of the United States of America . 1984;81(7):1996&#x2013;2000. doi: 10.1073/pnas.81.7.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.81.7.1996</ArticleId><ArticleId IdType="pmc">PMC345423</ArticleId><ArticleId IdType="pubmed">6201849</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A. Y. S., Reed J. H., Gordon T. P. Anti-ro60 and anti-ro52/trim21: two distinct autoantibodies in systemic autoimmune diseases. Journal of Autoimmunity . 2021;124, article 102724 doi: 10.1016/j.jaut.2021.102724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102724</ArticleId><ArticleId IdType="pubmed">34464814</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccitto M., Wolin S. L. Ro60 and y rnas: structure, functions, and roles in autoimmunity. Critical Reviews in Biochemistry and Molecular Biology . 2019;54(2):133&#x2013;152. doi: 10.1080/10409238.2019.1608902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10409238.2019.1608902</ArticleId><ArticleId IdType="pmc">PMC6542706</ArticleId><ArticleId IdType="pubmed">31084369</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiboski C. H., Shiboski S. C., Seror R., et al. 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sj&#xf6;gren's syndrome. Annals of the Rheumatic Diseases . 2017;76(1):9&#x2013;16. doi: 10.1136/annrheumdis-2016-210571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-210571</ArticleId><ArticleId IdType="pubmed">27789466</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss S., Watkinson R., Sandlie I., James L. C., Andersen J. T. TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunological Reviews . 2015;268(1):328&#x2013;339. doi: 10.1111/imr.12363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12363</ArticleId><ArticleId IdType="pmc">PMC4670481</ArticleId><ArticleId IdType="pubmed">26497531</ArticleId></ArticleIdList></Reference><Reference><Citation>Retamozo S., Akasbi M., Brito-Zer&#xf3;n P., et al. Anti-ro52 antibody testing influences the classification and clinical characterisation of primary Sj&#xf6;gren's syndrome. Clinical and Experimental Rheumatology . 2012;30(5):686&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">22704838</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutjes S. A., Egberts W. T. V., Jongen P., Van Den Hoogen F., Pruijn G. J., Van Venrooij W. J. Anti-ro52 antibodies frequently co-occur with anti-jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clinical and Experimental Immunology . 1997;109(1):32&#x2013;40. doi: 10.1046/j.1365-2249.1997.4081308.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1997.4081308.x</ArticleId><ArticleId IdType="pmc">PMC1904727</ArticleId><ArticleId IdType="pubmed">9218821</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson M., Pope J., Mahler M., et al. Clinical significance of antibodies to ro52/trim21 in systemic sclerosis. Arthritis Research &amp; Therapy . 2012;14(2, article R50) doi: 10.1186/ar3763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3763</ArticleId><ArticleId IdType="pmc">PMC3446416</ArticleId><ArticleId IdType="pubmed">22394602</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X., Zhou J., Guo X., et al. A retrospective analysis of distinguishing features of chest hrct and clinical manifestation in primary Sj&#xf6;gren's syndrome-related interstitial lung disease in a Chinese population. Clinical Rheumatology . 2018;37(11):2981&#x2013;2988. doi: 10.1007/s10067-018-4289-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4289-6</ArticleId><ArticleId IdType="pubmed">30242640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson R., El-Hage F., Aal&#xf8;kken T. M., et al. Associations between anti-ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology . 2016;55(1):103&#x2013;108. doi: 10.1093/rheumatology/kev300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev300</ArticleId><ArticleId IdType="pubmed">26320136</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitch-Rogalsky C., Steber W., Mahler M., et al. Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One . 2014;9(4, article e93812) doi: 10.1371/journal.pone.0093812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0093812</ArticleId><ArticleId IdType="pmc">PMC3976309</ArticleId><ArticleId IdType="pubmed">24705829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hervier B., Rimbert M., Colonna F., Hamidou M. A., Audrain M. Clinical significance of anti-ro/ssa-52 kda antibodies--a retrospective monocentric study. Rheumatology . 2009;48(8):964&#x2013;967. doi: 10.1093/rheumatology/kep145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep145</ArticleId><ArticleId IdType="pubmed">19531627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanos D. P., Gkoutzourelas A., Papadopoulos V., et al. Anti-ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer. Clinica Chimica Acta . 2021;521:199&#x2013;205. doi: 10.1016/j.cca.2021.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.07.006</ArticleId><ArticleId IdType="pubmed">34245687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampeli E., Mavrommati M., Moutsopoulos H. M., Skopouli F. N. Anti-ro52 and/or anti-ro60 immune reactivity: autoantibody and disease associations. Clinical and Experimental Rheumatology . 2020;38(4) Supplement 126:134&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">32083547</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins A., Hentzien M., Toquet S., et al. Diagnostic utility of separate anti-ro60 and anti-ro52/trim21 antibody detection in autoimmune diseases. Frontiers in Immunology . 2019;10:p. 444. doi: 10.3389/fimmu.2019.00444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00444</ArticleId><ArticleId IdType="pmc">PMC6423153</ArticleId><ArticleId IdType="pubmed">30915082</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M., Orbai A. M., Alarc&#xf3;n G. S., et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism . 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M. C. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism . 1997;40(9):p. 1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., et al. 2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis &amp; Rheumatology . 2019;71(9):1400&#x2013;1412. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitali C., Bombardieri S., Jonsson R., et al. Classification criteria for Sj&#xf6;gren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Annals of the Rheumatic Diseases . 2002;61(6):554&#x2013;558. doi: 10.1136/ard.61.6.554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.61.6.554</ArticleId><ArticleId IdType="pmc">PMC1754137</ArticleId><ArticleId IdType="pubmed">12006334</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiboski S. C., Shiboski C. H., Criswell L., et al. American college of rheumatology classification criteria for Sj&#xf6;gren's syndrome: a data-driven, expert consensus approach in the Sj&#xf6;gren's international collaborative clinical alliance cohort. Arthritis Care &amp; Research . 2012;64(4):475&#x2013;487. doi: 10.1002/acr.21591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21591</ArticleId><ArticleId IdType="pmc">PMC3349440</ArticleId><ArticleId IdType="pubmed">22563590</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D., Neogi T., Silman A. J., et al. 2010 rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis and Rheumatism . 2010;62(9):2569&#x2013;2581. doi: 10.1002/art.27584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27584</ArticleId><ArticleId IdType="pubmed">20872595</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett F. C., Edworthy S. M., Bloch D. A., et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism . 1988;31(3):315&#x2013;324. doi: 10.1002/art.1780310302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780310302</ArticleId><ArticleId IdType="pubmed">3358796</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Hoogen F., Khanna D., Fransen J., et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases . 2013;72(11):1747&#x2013;1755. doi: 10.1136/annrheumdis-2013-204424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204424</ArticleId><ArticleId IdType="pubmed">24092682</ArticleId></ArticleIdList></Reference><Reference><Citation>Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis and Rheumatism . 1980;23(5):581&#x2013;590. doi: 10.1002/art.1780230510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780230510</ArticleId><ArticleId IdType="pubmed">7378088</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M., Neri R., Bombardieri S. Undifferentiated connective tissue diseases (uctd): a review of the literature and a proposal for preliminary classification criteria. Clinical and Experimental Rheumatology . 1999;17(5):615&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">10544849</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohan A., Peter J. B. Polymyositis and dermatomyositis. The New England Journal of Medicine . 1975;292(8):403&#x2013;407. doi: 10.1056/NEJM197502202920807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197502202920807</ArticleId><ArticleId IdType="pubmed">1089199</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu N., Watts R., Bajema I., et al. Eular points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases . 2010;69(10):1744&#x2013;1750. doi: 10.1136/ard.2009.119032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.119032</ArticleId><ArticleId IdType="pubmed">20448283</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S., Lockshin M. D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (aps) Journal of Thrombosis and Haemostasis . 2006;4(2):295&#x2013;306. doi: 10.1111/j.1538-7836.2006.01753.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudwaleit M., Landew&#xe9; R., Van Der Heijde D., et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part i): classification of paper patients by expert opinion including uncertainty appraisal. Annals of the Rheumatic Diseases . 2009;68(6):770&#x2013;776. doi: 10.1136/ard.2009.108217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.108217</ArticleId><ArticleId IdType="pubmed">19297345</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudwaleit M., Van Der Heijde D., Landew&#xe9; R., et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part ii): validation and final selection. Annals of the Rheumatic Diseases . 2009;68(6):777&#x2013;783. doi: 10.1136/ard.2009.108233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.108233</ArticleId><ArticleId IdType="pubmed">19297344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudwaleit M., Van Der Heijde D., Landew&#xe9; R., et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases . 2011;70(1):25&#x2013;31. doi: 10.1136/ard.2010.133645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.133645</ArticleId><ArticleId IdType="pubmed">21109520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasukawa R. Mixed connective tissue disease. Internal Medicine . 1999;38(5):386&#x2013;393. doi: 10.2169/internalmedicine.38.386.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.38.386</ArticleId><ArticleId IdType="pubmed">10397074</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S., Tang X., Wu L., Lu L., Feng X. Anti-ro52 antibodies in clinical practice: a single-centre experience. International Journal of Clinical Practice . 2021;75(3, article e13679) doi: 10.1111/ijcp.13679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13679</ArticleId><ArticleId IdType="pubmed">32798318</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Pelkum J., Fritzler M., Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmunity Reviews . 2009;8(7):632&#x2013;637. doi: 10.1016/j.autrev.2009.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2009.02.010</ArticleId><ArticleId IdType="pubmed">19393201</ArticleId></ArticleIdList></Reference><Reference><Citation>Men&#xe9;ndez A., G&#xf3;mez J., Caminal-Montero L., D&#xed;az-L&#xf3;pez J. B., Cabezas-Rodr&#xed;guez I., Mozo L. Common and specific associations of anti-ssa/ro60 and anti-ro52/trim21 antibodies in systemic lupus erythematosus. The Scientific World Journal . 2013;2013:8. doi: 10.1155/2013/832789.832789</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/832789</ArticleId><ArticleId IdType="pmc">PMC3833022</ArticleId><ArticleId IdType="pubmed">24294139</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa A., Zhou W., Ek M., et al. The Sjogren's syndrome-associated autoantigen ro52 is an e3 ligase that regulates proliferation and cell death. Journal of Immunology . 2006;176(10):6277&#x2013;6285. doi: 10.4049/jimmunol.176.10.6277.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.10.6277</ArticleId><ArticleId IdType="pubmed">16670339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinal-Fernandez I., Casal-Dominguez M., Huapaya J. A., et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-pl7 and anti-pl12 autoantibodies. Rheumatology . 2017;56(6):999&#x2013;1007. doi: 10.1093/rheumatology/kex021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex021</ArticleId><ArticleId IdType="pmc">PMC5850781</ArticleId><ArticleId IdType="pubmed">28339994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan Ali O., Bomze D., Risch L., et al. Severe coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (ig) a and antiphospholipid Iga antibodies. Clinical Infectious Diseases . 2021;73(9):e2869&#x2013;e2874. doi: 10.1093/cid/ciaa1496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1496</ArticleId><ArticleId IdType="pmc">PMC7543315</ArticleId><ArticleId IdType="pubmed">32997739</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing X., Li A., Li C. _Anti_ -Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respiratory Medicine . 2020;172, article 106134 doi: 10.1016/j.rmed.2020.106134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106134</ArticleId><ArticleId IdType="pubmed">32905890</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu A., Ye Y., Fu Q., et al. Prognostic values of anti-ro52 antibodies in anti-mda5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology . 2021;60(7):3343&#x2013;3351. doi: 10.1093/rheumatology/keaa786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa786</ArticleId><ArticleId IdType="pubmed">33331866</ArticleId></ArticleIdList></Reference><Reference><Citation>Marie I., Hatron P. Y., Dominique S., et al. Short-term and long-term outcome of anti-jo1-positive patients with anti-ro52 antibody. Seminars in Arthritis and Rheumatism . 2012;41(6):890&#x2013;899. doi: 10.1016/j.semarthrit.2011.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.09.008</ArticleId><ArticleId IdType="pubmed">22078416</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonk M. C., Vandecasteele E., van Dijk A. Pulmonary hypertension in connective tissue diseases, new evidence and challenges. European Journal of Clinical Investigation . 2021;51(4, article e13453) doi: 10.1111/eci.13453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13453</ArticleId><ArticleId IdType="pmc">PMC7988614</ArticleId><ArticleId IdType="pubmed">33216992</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker P., Moulinet T., Lopez B., et al. Clinical significance of anti-ro52 (trim21) antibodies in adult patients with connective tissue diseases. European Journal of Internal Medicine . 2021;91:45&#x2013;52. doi: 10.1016/j.ejim.2021.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.04.020</ArticleId><ArticleId IdType="pubmed">33972152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A., Patterson K. A., Tan D. J., et al. Anti-ro52/trim21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients. Scandinavian Journal of Rheumatology . 2021;50(6):469&#x2013;474. doi: 10.1080/03009742.2021.1887927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2021.1887927</ArticleId><ArticleId IdType="pubmed">33851896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W., Xin Z., Ning X., et al. Clinical features and risk factors of Raynaud's phenomenon in primary Sj&#xf6;gren's syndrome. Clinical Rheumatology . 2021;40(10):4081&#x2013;4087. doi: 10.1007/s10067-021-05749-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05749-w</ArticleId><ArticleId IdType="pmc">PMC8463379</ArticleId><ArticleId IdType="pubmed">33914202</ArticleId></ArticleIdList></Reference><Reference><Citation>Menor Almagro R., Jurado Roger A., Rodr&#xed;guez Guti&#xe9;rrez F. J., Sol&#xed;s D&#xed;az R., Cardiel M. H., Salaberri Maestrojuan J. J. Asociacion de los anticuerpos anti-Ro52, anti-Ro60 y anti-La con las caracteristicas diagnosticas, clinicas y de laboratorio en un hospital de referencia en Jerez, Espa&#xf1;a. Reumatolog&#xed;a Cl&#xed;nica . 2016;12(5):256&#x2013;262. doi: 10.1016/j.reuma.2015.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2015.10.010</ArticleId><ArticleId IdType="pubmed">26725021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerli R., Muscat C., Giansanti M., et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sj&#xf6;gren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. British Journal of Rheumatology . 1997;36(9):969&#x2013;975. doi: 10.1093/rheumatology/36.9.969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/36.9.969</ArticleId><ArticleId IdType="pubmed">9376993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruacho G., Kvarnstr&#xf6;m M., Zickert A., et al. Sj&#xf6;gren syndrome in systemic lupus erythematosus: a subset characterized by a systemic inflammatory state. The Journal of Rheumatology . 2020;47(6):865&#x2013;875. doi: 10.3899/jrheum.190250.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.190250</ArticleId><ArticleId IdType="pubmed">31523050</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe1;l I., Lakos G., Zeher M. Comparison of the anti-ro/ssa autoantibody profile between patients with primary and secondary Sjogren's Syndrome. Autoimmunity . 2000;32(2):89&#x2013;92. doi: 10.3109/08916930008994077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916930008994077</ArticleId><ArticleId IdType="pubmed">11078154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>